Skip to main content
Biocorp logo

Biocorp — Investor Relations & Filings

Ticker · ALCOR ISIN · FR0012788065 LEI · 969500TKUAME6031UQ32 PA Manufacturing
Open in API
Filings indexed 235 across all filing types
Latest filing 2018-05-24 M&A Activity
Country FR France
Listing PA ALCOR

About Biocorp

https://biocorpsys.com

Biocorp designs, develops, and manufactures medical devices and drug delivery systems for the pharmaceutical industry. The company specializes in combining precision engineering with connected technologies to improve patient treatment adherence and outcomes. Its portfolio includes both connected and non-connected devices, such as smart caps for inhalers (Inspair), pen injectors, and systems for drug reconstitution and safety. Biocorp manages the entire value chain, from research and development to manufacturing and final packaging, leveraging its expertise in plastics processing and advanced technological innovation. Since October 2023, Biocorp has been a subsidiary of Novo Nordisk.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
M&A Activity Classification · 1% confidence The document details a significant commercial agreement between BIOCORP and CHRONICARE, outlining financial terms, revenue projections over five years, licensing fees, and equity stakes. This content focuses on a major business development, financing/partnership structure, and associated revenue potential, rather than routine periodic financial results (ER/IR), management changes (MANG), or shareholder voting (DVA). It is a specific announcement detailing a strategic business transaction and its financial implications, which aligns best with the 'Capital/Financing Update' (CAP) category, as it involves securing significant guaranteed revenue streams and an equity investment, fundamentally altering the company's financial outlook through a partnership. While it is not a traditional capital raise, the securing of guaranteed future revenue and equity stake is a major capital/financing event for a company of this size. It is too specific for a general Regulatory Filing (RNS) and does not fit the other categories.
2018-05-24 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release ("Communiqué de presse") announcing that BIOCORP confirms its eligibility for the PEA-PME investment scheme for 2018-2019, citing specific French regulatory decrees. This announcement relates to the company's capital structure eligibility for certain investors, which falls under financing or capital structure updates. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). The most fitting category is Capital/Financing Update (CAP), as it directly concerns the conditions under which its shares can be held for tax-advantaged investment purposes, which is a financing/capital structure matter. Given the specific nature of the announcement (eligibility criteria confirmation rather than a fundraising event), CAP is the best fit among the provided options.
2018-04-16 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
M&A Activity Classification · 1% confidence The document announces that BIOCORP is repurchasing rights related to its Newseal and Carpseal systems from a former licensee (NUOVA OMPI) due to divergent strategies, leading to an amicable contract termination. This involves a financial transaction (repurchase of rights for 137.5 K€) and a related accounting charge (provision of 2,370,880 €). This type of announcement, detailing a significant business transaction, contract termination, and associated financial impact outside of standard periodic reporting (like 10-K or IR), best fits the 'Capital/Financing Update' (CAP) if it involved raising capital, or more generally, a significant corporate action. Since it details the termination of a licensing agreement and the repurchase of associated rights, it is a material corporate event. Given the options, it is not a standard earnings release (ER), management discussion (MDA), or a simple dividend notice (DIV). It is a specific announcement about a change in corporate assets/agreements. While it involves a financial element (repurchase cost), it is fundamentally about a change in business structure/agreements. In the context of the provided definitions, 'Capital/Financing Update' (CAP) is often used for significant corporate transactions that alter the structure or assets, which this repurchase qualifies as. Alternatively, if it were purely a regulatory disclosure of a material event not covered elsewhere, 'RNS' would apply. However, the core event is the acquisition/repurchase of intellectual property rights, which is a significant corporate transaction. Given the focus on the repurchase of rights and the associated financial impact, CAP is the most fitting category for a significant, non-routine corporate transaction announcement.
2018-02-19 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release announcing a strategic partnership between BIOCORP and CHRONICARE regarding a medication adherence solution. It details the agreement, the technology involved (EasylogTM integration), and includes quotes from executives. This type of announcement, which details a significant business development or agreement but is not a formal regulatory filing like a 10-K, earnings release (ER), or capital change (CAP), most closely aligns with a general business update or news release. Since there is no specific category for 'Partnership Announcement' or 'Press Release', and it is not a formal financial report, it falls best under the general regulatory/miscellaneous filing category, RNS (Regulatory Filings), as it is an official communication to the market about a material event.
2018-02-16 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de Presse" (Press Release) and announces a strategic partnership between BIOCORP and CHRONICARE regarding the distribution of the Easylog sensor in North America. It details the agreement, the product involved (a smart sensor for insulin pens), and includes quotes from the management of both companies. This format—a formal announcement of a business development, partnership, or significant event, issued to the public via press release—does not fit the specific regulatory filing types like 10-K, IR, ER, or DVA. Since it is a formal announcement of a business development (a strategic partnership), it is best classified as a general Regulatory Filing (RNS) or potentially a general announcement, but RNS serves as the best fit for non-standard, material press releases that aren't covered by other specific codes. Given the context of financial reporting databases, press releases announcing material business events often fall under the general regulatory announcement category if a more specific code like M&A (TAR) or Financing (CAP) does not apply. This is a partnership announcement, which is a material event.
2018-02-16 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the issuance of convertible bonds (obligations convertibles) worth €4 million. This action directly relates to the company's financing activities and capital structure changes (raising capital via debt convertible into equity). Based on the definitions, this aligns perfectly with the 'Capital/Financing Update' category. Filing Type Code: CAP (Capital/Financing Update).
2018-02-13 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.